Intermediate hepatocellular carcinoma: the role of transarterial therapy

References

• European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer . EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol.56(4), 908–943 (2012).
   PubMed Web of Science ®Google Scholar
• Kim WR , GoresGJ, BensonJT, TherneauTM, MeltonLJ. Mortality and hospital utilization for hepatocellular carcinoma in the United States. Gastroenterology129(2), 486–493 (2005).
   PubMed Web of Science ®Google Scholar
• Tsochatzis E , MeyerT, O'BeirneJ, BurroughsAK. Transarterial chemoembolisation is not superior to embolisation alone: the recent European Association for the Study of the Liver (EASL) – European Organisation for Research and Treatment of Cancer (EORTC) guidelines. Eur. J. Cancer49(6), 1509–1510 (2013).
   PubMed Web of Science ®Google Scholar
• Raoul J-L , SangroB, FornerAet al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat. Rev.37(3), 212–220 (2011).
   PubMed Web of Science ®Google Scholar
• Lewandowski RJ , GeschwindJ-F, LiapiE, SalemR. Transcatheter intraarterial therapies: rationale and overview. Radiology259(3), 641–657 (2011).
   PubMed Web of Science ®Google Scholar
• Pieper CC , MeyerC, VollmarB, HauensteinK, SchildHH, WilhelmKE. Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCept® S) in a swine model. Cardiovasc. Intervent. Radiol.38(2), 435–441 (2015).
   PubMed Web of Science ®Google Scholar
• Deipolyi AR , OkluR, Al-AnsariS, ZhuAX, GoyalL, GanguliS. Safety and efficacy of 70–150 μm and 100–300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol.26(4), 516–522 (2015).
   PubMed Web of Science ®Google Scholar
• Marelli L , StiglianoR, TriantosCet al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc. Intervent. Radiol.30(1), 6–25 (2007).
   PubMed Web of Science ®Google Scholar
• Gish RG , LencioniR, Di BisceglieAM, RaoulJL, MazzaferroV. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev. Gastroenterol. Hepatol.6(2), 173–185 (2012).
   PubMed Web of Science ®Google Scholar
• Markowitz J . The hepatic artery. Surg. Gynecol. Obstet.95(5), 644–646 (1952).
   PubMedGoogle Scholar
• Bierman HR , ByronRL, KelleyKH, GradyA. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J. Natl Cancer Inst.12(1), 107–131 (1951).
   PubMedGoogle Scholar
• Doyon D , MouzonA, JourdeAM, RegensbergC, FrileuxC. Hepatic, arterial embolization in patients with malignant liver tumours (author's transl.). Ann. Radiol. (Paris).17(6), 593–603 (1974).
   PubMedGoogle Scholar
• Gyves JW , ZiessmanHA, EnsmingerWDet al. Definition of hepatic tumor microcirculation by single photon emission computerized tomography (SPECT). J. Nucl. Med.25(9), 972–967 (1984).
   PubMed Web of Science ®Google Scholar
• Bonomo G , PediciniV, MonfardiniLet al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc. Intervent. Radiol.33(3), 552–559 (2010).
   PubMed Web of Science ®Google Scholar
• Erinjeri JP , SalhabHM, CoveyAM, GetrajdmanGI, BrownKT. Arterial patency after repeated hepatic artery bland particle embolization. J. Vasc. Interv. Radiol.21(4), 522–526 (2010).
   PubMed Web of Science ®Google Scholar
• Tsochatzis E , MeyerT, MarelliL, BurroughsAK. Which transarterial therapy is best for hepatocellular carcinoma? The evidence to date. J. Hepatol.53(3), 588 (2010).
   PubMed Web of Science ®Google Scholar
• Coldwell DM , StokesKR, YakesWF. Embolotherapy: agents, clinical applications, and techniques. Radiographics14(3), 623–643 (1994).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RealMI, MontañaXet al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359(9319), 1734–1739 (2002).
   PubMed Web of Science ®Google Scholar
• Brown DB , PilgramTK, DarcyMDet al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J. Vasc. Interv. Radiol.16(12), 1661–1666 (2005).
   PubMed Web of Science ®Google Scholar
• Brown KT , NevinsAB, GetrajdmanGIet al. Particle embolization for hepatocellular carcinoma. J. Vasc. Interv. Radiol.9(5), 822–828 (1998).
   PubMed Web of Science ®Google Scholar
• Maluccio M , CoveyAM, GandhiRet al. Comparison of survival rates after bland arterial embolization and ablation versus surgical resection for treating solitary hepatocellular carcinoma up to 7 cm. J. Vasc. Interv. Radiol.16(7), 955–961 (2005).
   PubMed Web of Science ®Google Scholar
• Covey AM , MaluccioMA, SchubertJet al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer106(10), 2181–2189 (2006).
   PubMed Web of Science ®Google Scholar
• Osuga K , HoriS, HiraishiKet al. Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres. Cardiovasc. Intervent. Radiol.31(6), 1108–1116 (2008).
   PubMed Web of Science ®Google Scholar
• Rand T , LoeweC, SchoderMet al. Arterial embolization of unresectable hepatocellular carcinoma with use of microspheres, Lipiodol, and cyanoacrylate. Cardiovasc. Intervent. Radiol.28(3), 313–318 (2005).
   PubMed Web of Science ®Google Scholar
• Maluccio MA , CoveyAM, PoratLBet al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J. Vasc. Interv. Radiol.19(6), 862–869 (2008).
   PubMed Web of Science ®Google Scholar
• Oliveri RS , WetterslevJ, GluudC. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst. Rev.3, CD004787 (2011).
   PubMedGoogle Scholar
• Miyayama S , MatsuiO, TakiKet al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization. Cardiovasc. Intervent. Radiol.29(1), 39–48 (2006).
   PubMed Web of Science ®Google Scholar
• Kalayci C , JohnsonPJ, RabyN, MetivierEM, WilliamsR. Intraarterial adriamycin and Lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J. Hepatol.11(3), 349–353 (1990).
   PubMed Web of Science ®Google Scholar
• Yamada R , SatoM, KawabataM, NakatsukaH, NakamuraK, TakashimaS. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology148(2), 397–401 (1983).
   PubMed Web of Science ®Google Scholar
• Chang JM , TzengWS, PanHB, YangCF, LaiKH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer74(9), 2449–2453 (1994).
   PubMed Web of Science ®Google Scholar
• Kruskal JB , HlatkyL, HahnfeldtP, TeramotoK, StokesKR, ClouseME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J. Vasc. Interv. Radiol.4(6), 741–747 (1993).
   PubMedGoogle Scholar
• Lo CM , NganH, TsoWKet al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology35(5), 1164–1171 (2002).
   PubMed Web of Science ®Google Scholar
• Kawai S , TaniM, OkamuraJet al. Prospective and randomized trial of Lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment. Semin. Oncol.24(2 Suppl. 6), S6-38–S6-45 (1997).
   Web of Science ®Google Scholar
• Bhattacharya S , DhillonAP, WinsletMCet al. Human liver cancer cells and endothelial cells incorporate iodised oil. Br. J. Cancer73(7), 877–881 (1996).
   PubMed Web of Science ®Google Scholar
• Terayama N , MatsuiO, GabataTet al. Accumulation of iodized oil within the non-neoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc. Intervent. Radiol.24(6), 383–387 (2001).
   PubMed Web of Science ®Google Scholar
• Kan Z , McCuskeyPA, WrightKC, WallaceS. Role of Kupffer cells in iodized oil embolization. Invest. Radiol.29(11), 990–903 (1994).
   PubMed Web of Science ®Google Scholar
• Kan Z , WrightK, WallaceS. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models. Acad. Radiol.4(4), 275–282 (1997).
   PubMed Web of Science ®Google Scholar
• Llovet JM , BruixJ. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology37(2), 429–442 (2003).
   PubMed Web of Science ®Google Scholar
• Takayasu K , AriiS, IkaiIet al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology131(2), 461–469 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou WP , LaiECH, LiAJet al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann. Surg.249(2), 195–202 (2009).
   PubMed Web of Science ®Google Scholar
• Grieco A , MarcocciaS, MieleLet al. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology50(49), 207–212 (2003).
   PubMedGoogle Scholar
• Biolato M , MieleL, VeroVet al. Hepatocellular carcinoma treated by conventional transarterial chemoembolization in field-practice: serum sodium predicts survival. World J. Gastroenterol.20(25), 8158–8165 (2014).
   PubMed Web of Science ®Google Scholar
• Brown DB , GouldJE, GervaisDAet al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J. Vasc. Interv. Radiol.20(Suppl. 7), S425–S434 (2009).
   PubMed Web of Science ®Google Scholar
• Nicolini A , MartinettiL, CrespiS, MaggioniM, SangiovanniA. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J. Vasc. Interv. Radiol.21(3), 327–332 (2010).
   PubMed Web of Science ®Google Scholar
• Hong K , KhwajaA, LiapiE, TorbensonMS, GeorgiadesCS, GeschwindJFH. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin. Cancer Res.12(8), 2563–2567 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis AL , GonzalezMV, LloydAWet al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J. Vasc. Interv. Radiol.17(2), 335–342 (2006).
   PubMed Web of Science ®Google Scholar
• Lencioni R , de BaereT, BurrelMet al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc. Intervent. Radiol.35(5), 980–985 (2012).
   PubMed Web of Science ®Google Scholar
• Lee K-H , LiapiEA, CornellCet al. Doxorubicin-loaded QuadraSphere® microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc. Intervent. Radiol.33(3), 576–582 (2010).
   PubMed Web of Science ®Google Scholar
• Malagari K , AlexopoulouE, ChatzimichailKet al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom. Imaging33(5), 512–519 (2008).
   PubMedGoogle Scholar
• Varela M , RealMI, BurrelMet al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J. Hepatol.46(3), 474–481 (2007).
   PubMed Web of Science ®Google Scholar
• Poon RTP , TsoWK, PangRWCet al. A Phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin. Gastroenterol. Hepatol.5(9), 1100–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Reyes DK , VossenJA, KamelIRet al. Single-center Phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J.15(6), 526–532 (2009).
   PubMed Web of Science ®Google Scholar
• Lammer J , MalagariK, VoglTet al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol.33(1), 41–52 (2010).
   PubMed Web of Science ®Google Scholar
• Kalva SP , PectasidesM, LiuRet al. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc. Intervent. Radiol.37(2), 381–387 (2013).
   PubMed Web of Science ®Google Scholar
• Prajapati HJ , XingM, SpiveyJRet al. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR. Am. J. Roentgenol.203(6), W706–W714 (2014).
   PubMed Web of Science ®Google Scholar
• Lencioni R . Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit. Rev. Oncol. Hematol.83(2), 216–224 (2012).
   PubMed Web of Science ®Google Scholar
• Lencioni R , PetruzziP, CrocettiL. Chemoembolization of hepatocellular carcinoma. Semin. Intervent. Radiol.30(1), 3–11 (2013).
   PubMed Web of Science ®Google Scholar
• Zhu AX , DudaDG, SahaniD V, JainRK. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol.8(5), 292–301 (2011).
   PubMed Web of Science ®Google Scholar
• Wu XZ , XieGR, ChenD. Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol.22(8), 1178–1182 (2007).
   PubMed Web of Science ®Google Scholar
• Minata M , HaradaKH, KudoM, IkaiI, NishidaN. The prognostic value of vascular endothelial growth factor in hepatocellular carcinoma for predicting metastasis after curative resection. Oncology84(Suppl. 1), 75–81 (2013).
   PubMedGoogle Scholar
• Wiggermann P , WohlgemuthWA, HeiblMet al. Dynamic evaluation and quantification of microvascularization during degradable starch microspheres transarterial chemoembolisation (DSM-TACE) of HCC lesions using contrast enhanced ultrasound (CEUS): a feasibility study. Clin. Hemorheol. Microcirc.53(4), 337–348 (2013).
   PubMed Web of Science ®Google Scholar
• Potente M , GerhardtH, CarmelietP. Basic and therapeutic aspects of angiogenesis. Cell146(6), 873–887 (2011).
   PubMed Web of Science ®Google Scholar
• Forsberg JO . Transient blood flow reduction induced by intra-arterial injection of degradable starch microspheres: experiments on rats. Acta Chir. Scand.144(5), 275–281 (1978).
   PubMedGoogle Scholar
• Taguchi T . Chemo-occlusion for the treatment of liver cancer. A new technique using degradable starch microspheres. Clin. Pharmacokinet.26(4), 275–291 (1994).
   PubMed Web of Science ®Google Scholar
• Nishiofuku H , TanakaT, MatsuokaMet al. Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a Phase I/II study. J. Vasc. Interv. Radiol.24(1), 56–65 (2013).
   PubMed Web of Science ®Google Scholar
• Furuse J , IshiiH, SatakeMet al. Pilot study of transcatheter arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma. Am. J. Clin. Oncol.26(2), 159–164 (2003).
   PubMed Web of Science ®Google Scholar
• Kirchhoff TD , RudolphKL, LayerGet al. Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur. J. Surg. Oncol.32(2), 201–207 (2006).
   PubMed Web of Science ®Google Scholar
• Kirchhoff TD , BleckJS, DettmerAet al. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat. Dis. Int.6(3), 259–266 (2007).
   PubMed Web of Science ®Google Scholar
• Yamasaki T , HamabeS, SaekiIet al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J. Gastroenterol.46(3), 359–366 (2011).
   PubMed Web of Science ®Google Scholar
• Niessen C , UnterpaintnerE, GoessmannHet al. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. J. Vasc. Interv. Radiol.25(2), 240–247 (2014).
   PubMed Web of Science ®Google Scholar
• Ingold JA , ReedGB, KaplanHS, BagshawMA. Radiation hepatitis. Am. J. Roentgenol. Radium Ther. Nucl. Med.93, 200–208 (1965).
   PubMedGoogle Scholar
• Dawson LA , McGinnCJ, NormolleDet al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J. Clin. Oncol.18(11), 2210–2218 (2000).
   PubMed Web of Science ®Google Scholar
• Salem R , LewandowskiRJ, AtassiBet al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J. Vasc. Interv. Radiol.16(12), 1627–1639 (2005).
   PubMed Web of Science ®Google Scholar
• Salem R , LewandowskiRJ, KulikLet al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology140(2), 497–507.e2 (2011).
   PubMed Web of Science ®Google Scholar
• Hilgard P , HamamiM, FoulyA Elet al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology52(5), 1741–1749 (2010).
   PubMed Web of Science ®Google Scholar
• Mazzaferro V , SpositoC, BhooriSet al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a Phase 2 study. Hepatology57(5), 1826–1837 (2013).
   PubMed Web of Science ®Google Scholar
• Kennedy AS , NuttingC, ColdwellD, GaiserJ, DrachenbergC. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int. J. Radiat. Oncol. Biol. Phys.60(5), 1552–1563 (2004).
   PubMed Web of Science ®Google Scholar
• Kennedy A , NagS, SalemRet al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int. J. Radiat. Oncol. Biol. Phys.68(1), 13–23 (2007).
   PubMed Web of Science ®Google Scholar
• Sangro B , BilbaoJI, BoanJet al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys.66(3), 792–800 (2006).
   PubMed Web of Science ®Google Scholar
• Jung J , YoonSM, KimSYet al. Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat. Oncol.8, 249 (2013).
   PubMed Web of Science ®Google Scholar
• Gil-Alzugaray B , ChopiteaA, IñarrairaeguiMet al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology57(3), 1078–1087 (2013).
   PubMed Web of Science ®Google Scholar
• El Fouly A , ErtleJ, El DorryAet al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int. 35(2), 627–635 (2015).
   PubMed Web of Science ®Google Scholar
• Kim DY , ParkBJ, KimYHet al. Radioembolization with yttrium-90 resin microspheres in hepatocellular carcinoma: a multicenter prospective study. Am. J. Clin. Oncol.38(5), 495–501 (2015).
   PubMed Web of Science ®Google Scholar
• Balkwill F , MantovaniA. Inflammation and cancer: back to Virchow?Lancet357(9255), 539–545 (2001).
   PubMed Web of Science ®Google Scholar
• Coussens LM , WerbZ. Inflammation and cancer. Nature420(6917), 860–867 (2002).
   PubMed Web of Science ®Google Scholar
• Nakahara Y , MochidukiY, MiyamotoY, NakaharaY, KatsuraY. Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer104(6), 1271–1280 (2005).
   PubMed Web of Science ®Google Scholar
• Shimada H , TakiguchiN, KainumaOet al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer13(3), 170–176 (2010).
   PubMed Web of Science ®Google Scholar
• Sukato DC , TohmeS, ChalhoubDet al. The prognostic role of neutrophil-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma treated with radioembolization. J. Vasc. Interv. Radiol.26(6), 816–824.e1 (2015).
   PubMed Web of Science ®Google Scholar